(NASDAQ: SUPN) Supernus's forecast annual revenue growth rate of 3.56% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.15%.
Supernus's revenue in 2026 is $1,374,000,000.On average, 6 Wall Street analysts forecast SUPN's revenue for 2026 to be $158,993,511,384, with the lowest SUPN revenue forecast at $148,724,442,720, and the highest SUPN revenue forecast at $166,193,662,976. On average, 6 Wall Street analysts forecast SUPN's revenue for 2027 to be $166,311,698,248, with the lowest SUPN revenue forecast at $151,793,359,792, and the highest SUPN revenue forecast at $176,816,837,456.
In 2028, SUPN is forecast to generate $180,121,825,072 in revenue, with the lowest revenue forecast at $165,249,380,800 and the highest revenue forecast at $191,099,105,368.